- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06779773
En studie för att lära sig hur Avacincaptad Pegol (Izervay™) används i klinisk praxis hos personer som har geografisk atrofi
En icke-interventionell, observationsstudie för att utvärdera behandlingsmönster och säkerhet för Avacincaptad Pegol (ACP/IZERVAY™) i rutinmässig klinisk praxis hos patienter med geografisk atrofi sekundär till åldersrelaterad makuladegeneration
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision.
Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy.
This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas).
People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85053
- Retinal Consultants of AZ
-
Scottsdale, Arizona, Förenta staterna, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Laguna Hills, California, Förenta staterna, 92653
- Harvard Eye Associates
-
Orange, California, Förenta staterna, 92868
- University of California Irvine Medical Center
-
Redlands, California, Förenta staterna, 92374
- Retina Consultants of Southern CA
-
Sacramento, California, Förenta staterna, 95825
- Retinal Consultants Medical Group Inc
-
Torrance, California, Förenta staterna, 90503
- Retina Macula Institute
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Rocky Mountain Lions Eye Institute
-
Colorado Springs, Colorado, Förenta staterna, 80909
- Retina Consultants of Southern Colorado
-
Lakewood, Colorado, Förenta staterna, 80228
- Colorado Retina Associates, PLLC
-
-
Connecticut
-
Greenwich, Connecticut, Förenta staterna, 05830
- Coastal Eye Surgeons
-
-
Florida
-
Bonita Springs, Florida, Förenta staterna, 34134
- Advanced Retina Institute
-
Coral Gables, Florida, Förenta staterna, 33146
- University of Miami
-
Palm Beach Gardens, Florida, Förenta staterna, 33410
- Retina Care Specialists
-
Tampa, Florida, Förenta staterna, 33606
- Eye Physicians of Pinellas PA dba Eye Institute of West Florida
-
Wesley Chapel, Florida, Förenta staterna, 33544
- Retina Specialists of Tampa
-
-
Georgia
-
Augusta, Georgia, Förenta staterna, 30909
- Southeast Retina Center, P.C.
-
-
Illinois
-
Oak Forest, Illinois, Förenta staterna, 60452
- University Retina and Macula Associates, P.C.
-
Oak Park, Illinois, Förenta staterna, 60304
- Illinois Retina Associates
-
Peoria, Illinois, Förenta staterna, 61615
- Illinois Eye Center
-
-
Iowa
-
West Des Moines, Iowa, Förenta staterna, 50266
- Wolfe Eye Clinic
-
-
Maryland
-
Hagerstown, Maryland, Förenta staterna, 21740
- Cumberland Valley Retina Consultants,P.C.
-
-
Michigan
-
Grand Blanc, Michigan, Förenta staterna, 48439
- Retina Associates of Michigan
-
-
Minnesota
-
Saint Louis Park, Minnesota, Förenta staterna, 55416
- Retina Consultants of Minnesota PLLC
-
-
Mississippi
-
Madison, Mississippi, Förenta staterna, 39110
- Mississippi Retina Associates
-
Olive Branch, Mississippi, Förenta staterna, 38654
- Brown Family Retina PLLC
-
Southaven, Mississippi, Förenta staterna, 38671
- Deep Blue Retina Clinical Research
-
-
Nevada
-
Reno, Nevada, Förenta staterna, 89502
- Sierra Eye Associates
-
-
New Jersey
-
Dover, New Jersey, Förenta staterna, 07801
- Eye Associates of North Jersey PA
-
Edison, New Jersey, Förenta staterna, 08820
- NJ Retina
-
Lakewood, New Jersey, Förenta staterna, 08701
- NJ Retina
-
Toms River, New Jersey, Förenta staterna, 08755
- NJ Retina
-
-
New York
-
Brentwood, New York, Förenta staterna, 11717
- SightMD
-
Liverpool, New York, Förenta staterna, 13088
- Retina-Vitreous Surgeons of Central NY
-
Massapequa, New York, Förenta staterna, 11758
- NY Retina Ophthalmology PLLC
-
New York, New York, Förenta staterna, 10075
- Retina Associates of New York
-
Scarsdale, New York, Förenta staterna, 10583
- Long Island Vitreoretinal Consultants
-
Shirley, New York, Förenta staterna, 11967
- Vitreoretinal Consultants
-
-
North Carolina
-
Wake Forest, North Carolina, Förenta staterna, 27587
- North Carolina Retina Associates
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43221
- The Ohio State University
-
Dayton, Ohio, Förenta staterna, 45459
- CEI Physicians PSC, LLC dba
-
-
Oregon
-
Eugene, Oregon, Förenta staterna, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie, Pennsylvania, Förenta staterna, 16507
- Erie Retina Research
-
-
Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37920
- Southeastern Retina Associates, P.C.
-
Knoxville, Tennessee, Förenta staterna, 37923
- Southeastern Retina Associates, P.C.
-
Memphis, Tennessee, Förenta staterna, 38119
- Mid South Retina Associates
-
Nashville, Tennessee, Förenta staterna, 37203
- Tennessee Retina, PC
-
-
Texas
-
Abilene, Texas, Förenta staterna, 79606
- Retina Research Institute of Texas
-
Dallas, Texas, Förenta staterna, 75243
- Retina of North Texas
-
McAllen, Texas, Förenta staterna, 78503
- Valley Retina Institute
-
San Antonio, Texas, Förenta staterna, 78240
- Medical Center Ophthalmology Associates
-
San Antonio, Texas, Förenta staterna, 78240
- Retina Associates Of South Texas, Pa
-
-
Utah
-
Murray, Utah, Förenta staterna, 84107
- Retina Associates of Utah, P.C.
-
Salt Lake City, Utah, Förenta staterna, 84120
- Salt Lake Retina
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- The Retina Group of Washington
-
Lynchburg, Virginia, Förenta staterna, 24502
- Piedmont Eye Center, Inc.
-
Warrenton, Virginia, Förenta staterna, 20186
- Virginia Retina Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Retina & Vitreous Consultants of Wisconsin
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Participants from both academic and non-academic sites, urban and rural across the US to ensure a heterogenous population that is representative of the US GA secondary to AMD population and reflective of real-world practice patterns.
Beskrivning
Inclusion Criteria:
- Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes
- Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment
- Patient willingness to complete the patient reported outcome (PRO).
Exclusion Criteria:
-
Patients who have any contraindication or are not eligible for treatment with ACP, including the following:
- Active ocular or peri-ocular infection in either eye
- Active, suspected intraocular inflammation in either eye
- Hypersensitive to ACP or to any ingredient in the formulation
-
Patients currently participating in an investigational program with interventions outside of routine clinical practice.
-
Patients who have received ACP in the eye being considered for enrollment. Note: Patients who have received or are receiving ACP in the fellow eye at baseline are eligible to be included in the study.
-
Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Izervay
Patients with geographic atrophy (GA) secondary to AMD who have made decision to begin treatment with Izervay |
intravitreal injection
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of ACP injections
Tidsram: Up to 61 Months
|
The number of ACP injections. |
Up to 61 Months
|
|
Duration of treatment
Tidsram: Up to 61 Months
|
The duration of treatment will be calculated as the difference between the date of the last injection and the date of the first injection plus 31 days (as the next injection would be expected at least 30 days after the last one). |
Up to 61 Months
|
|
Annual frequency of ACP injection
Tidsram: Up to 61 Months
|
The annual frequency of ACP injections will be calculated as the total number of injections divided by the treatment duration in years. |
Up to 61 Months
|
|
Reasons for discontinuation of treatment with ACP
Tidsram: Up to 61 Months
|
The reasons for discontinuation of treatment with ACP will be recorded. |
Up to 61 Months
|
|
Duration of the treatment interval
Tidsram: Up to 61 Months
|
The treatment interval is defined as mean number of days between injections, if a study eye receives more than 1 injection. |
Up to 61 Months
|
|
Site characteristics
Tidsram: Day 1
|
Characteristics of interest will be recorded including the type of setting (e.g., public/private facility, rural/urban). |
Day 1
|
|
Characteristics of patients with geographic atrophy (GA) secondary to AMD beginning treatment with Izervay
Tidsram: Day 1
|
Characteristics of interest will be recorded. |
Day 1
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of participants with Adverse Events (AEs)
Tidsram: Up to 61 Months
|
An AE is defined as any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal (investigational) product. |
Up to 61 Months
|
|
Number of participants with Serious Adverse Events (SAEs)
Tidsram: Up to 61 Months
|
An SAE is defined as an AE that results in death, is life-threatening, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or other medically important events. |
Up to 61 Months
|
|
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Tidsram: Up to 61 Months
|
TEAE is defined an AE observed after starting administration of the study drug and will continue until 30 days after the last administration or until last study visit, whichever is sooner. |
Up to 61 Months
|
|
Number of participants with Adverse Event of Special Interest (AESI)
Tidsram: Up to 61 Months
|
AESIs are defined as the following AEs:
|
Up to 61 Months
|
|
Number of Participants maintaining vision
Tidsram: Up to 61 Months
|
Maintaining vision is defined as not losing ≥ 15 letters on Early Treatment Diabetic Retinopathy Study (ETDRS) chart. |
Up to 61 Months
|
|
Time to vision loss using various thresholds
Tidsram: Up to 61 Months
|
Time to vision loss is defined as the difference between the date when vision loss was reported for the first time and the start date of treatment. |
Up to 61 Months
|
|
Time to thresholds associated with ability to drive
Tidsram: Up to 61 Months
|
Time to thresholds associated with the ability to drive will be based on visual acuity data captured as per standard of care. |
Up to 61 Months
|
Samarbetspartners och utredare
Utredare
- Studierektor: Medical Director, Astellas Pharma Global Development, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 3021-MA-3543
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .